Several studies have been conducted on the role of ABCA1 and APOE in AD pathology and most of these have examined the effects of LXR and PPAR-γ agonists and genetic interventions (e.g. genetic overexpression or deletion of ABCA1). Here, PPARG is linked to Alzheimer disease.